<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">actabiomedica</journal-id><journal-title-group><journal-title xml:lang="ru">Acta Biomedica Scientifica</journal-title><trans-title-group xml:lang="en"><trans-title>Acta Biomedica Scientifica</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2541-9420</issn><issn pub-type="epub">2587-9596</issn><publisher><publisher-name>Scientific Centre for Family Health and Human Reproduction Problems</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.29413/ABS.2025-10.1.23</article-id><article-id custom-type="elpub" pub-id-type="custom">actabiomedica-5236</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ФАРМАКОЛОГИЯ И ФАРМАЦИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PHARMACOLOGY AND PHARMACEUTICS</subject></subj-group></article-categories><title-group><article-title>Влияние фитокомпозиции на дислипидемию у пациентов, перенёсших инфекцию SARS-CoV-2, на  санаторно-курортном этапе лечения</article-title><trans-title-group xml:lang="en"><trans-title>Effect of phytocomposition on dyslipidemia in patients with SARS-CoV-2 infection at the health resort stage of treatment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5486-7262</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яцков</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yatskov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Яцков Игорь Анатольевич – кандидат медицинских наук, доцент кафедры внутренней медицины № 2, </p><p>295000, г. Симферополь, б-р Ленина, 5-7</p></bio><bio xml:lang="en"><p>Igor A. Yatskov – Cand. Sc. (Med.), Associate Professor at the Department of Internal Medicine No. 2,</p><p>Lenina Blvd. 5-7, Simferopol 295000</p></bio><email xlink:type="simple">egermd@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1506-4758</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дудченко</surname><given-names>Л. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Dudchenko</surname><given-names>L. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дудченко Лейла Шамилевна – доктор медицинских наук, заведующая научно-исследовательским отделом пульмонологии, </p><p>298603, г. Ялта, ул. Мухина, 10/3</p></bio><bio xml:lang="en"><p>Leyla Sh. Dudchenko – Dr. Sc. (Med.), Head of the Research Department of Pulmonology,</p><p>Mukhina str. 10/3, Yalta 298603</p></bio><email xlink:type="simple">vistur@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2001-7585</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Меликов</surname><given-names>Ф. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Melikov</surname><given-names>F. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Меликов Фархад Маисович – кандидат фармацевтических наук, ведущий научный сотрудник лаборатории ароматических и лекарственных растений, </p><p>298648, г. Ялта, пгт Никита, Никитский спуск, 52</p></bio><bio xml:lang="en"><p>Farkhad M. Melikov – Cand. Sc. (Pharm.), Leading Research Officer at the Laboratory of Aromatic and Medicinal Plants,</p><p>Nikitsky slope 52, Nikita settlement, Yalta 298648</p></bio><email xlink:type="simple">f.melikov@mail.ru</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9640-754X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белоглазов</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Beloglazov</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Белоглазов Владимир Алексеевич – доктор медицинских наук, заведующий кафедрой внутренней медицины № 2, </p><p>295000, г. Симферополь, б-р Ленина, 5-7</p></bio><bio xml:lang="en"><p>Vladimir  A. Beloglazov – Dr.  Sc. (Med.), Head of  the  Department of  Internal Medicine No.  2,</p><p>Lenina Blvd. 5-7, Simferopol 295000</p></bio><email xlink:type="simple">biloglazov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7882-8885</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Соловьева</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Solovyova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Соловьёва Елена Александровна – научный сотрудник научно-исследовательского отдела пульмонологии, </p><p>298603, г. Ялта, ул. Мухина, 10/3</p></bio><bio xml:lang="en"><p>Elena A. Solovyova – Research Officer at the Research Department of Pulmonology, </p><p>Mukhina str. 10/3, Yalta 298603</p></bio><email xlink:type="simple">elenasolovjova0507@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1876-0011</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Андреева</surname><given-names>Г. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Andreeva</surname><given-names>G. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Андреева Галина Николаевна – научный сотрудник научно-исследовательского отдела пульмонологии, </p><p>298603, г. Ялта, ул. Мухина, 10/3</p></bio><bio xml:lang="en"><p>Galina N. Andreeva – Research Officer at the Research Department of Pulmonology, </p><p>Mukhina str. 10/3, Yalta 298603</p></bio><email xlink:type="simple">galinaandreeva2901@internet.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинский институт имени С.И. Георгиевского, ФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»</institution></aff><aff xml:lang="en"><institution>Medical Institute named after S.I. Georgievsky, V.I. Vernadsky Crimean Federal University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ РК «Академический научно-исследовательский институт физических методов лечения, медицинской климатологии и реабилитации им. И.М. Сеченова»</institution></aff><aff xml:lang="en"><institution>I.M. Sechenov Academic Research Institute for Physical Therapy, Medical Climatology and Rehabilitation</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>ФГБУН «Ордена Трудового Красного Знамени Никитский ботанический сад –&#13;
Национальный научный центр РАН»</institution></aff><aff xml:lang="en"><institution>The Order of the Red Banner of Labour Nikitsky Botanical Garden – National Scientific Centre of the Russian Academy of Sciences</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>21</day><month>03</month><year>2025</year></pub-date><volume>10</volume><issue>1</issue><fpage>221</fpage><lpage>229</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Яцков И.А., Дудченко Л.Ш., Меликов Ф.М., Белоглазов В.А., Соловьева Е.А., Андреева Г.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Яцков И.А., Дудченко Л.Ш., Меликов Ф.М., Белоглазов В.А., Соловьева Е.А., Андреева Г.Н.</copyright-holder><copyright-holder xml:lang="en">Yatskov I.A., Dudchenko L.S., Melikov F.M., Beloglazov V.A., Solovyova E.A., Andreeva G.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.actabiomedica.ru/jour/article/view/5236">https://www.actabiomedica.ru/jour/article/view/5236</self-uri><abstract><sec><title>Обоснование</title><p>Обоснование. Основной угрозой в постковидном периоде являются сердечно-сосудистые события, риск возникновения которых повышен у пациентов, перенёсших новую коронавирусную инфекцию (НКИ; SARS-CoV-2). В связи с этим особую актуальность имеет направление изучения коррекции уже хорошо изученных модифицируемых факторов риска. Одним из таких факторов, безусловно, является дислипидемия.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Изучение уровня липидов крови у больных после перенесённой новой коронавирусной инфекции и  возможности его  коррекции в период реабилитации в санаторно-курортных условиях с дополнительным применением фитотерапии.</p></sec><sec><title>Материалы и  методы</title><p>Материалы и  методы. В  исследование было включено 50  человек, перенёсших, по  данным анамнеза, инфекцию SARS-CoV-2 и  поступивших на санаторно-курортное лечение. Всем пациентам был проведён курс реабилитационных мероприятий продолжительностью 20 дней. До и после проведения курса реабилитационных мероприятий пациентам был выполнен лабораторный анализ, включавший основные биохимические показатели, в том числе общий холестерин, липопротеиды низкой плотности (ЛПНП), липопротеиды высокой плотности (ЛПВП) и триглицериды (ТГ). Респонденты были разделены на две группы – экспериментальную (группа № 1; n = 21) и контрольную (группа № 2; n = 29). Пациенты из группы № 1 в дополнение к стандартным мероприятиям получали чай из фитокомпозиции.</p></sec><sec><title>Результаты</title><p>Результаты. В  группе, получавшей чай на  основе растительной фитокомпозиции, отмечалось статистически значимое снижение показателей общего холестерина – с 6,91 ± 1,75 до 5,9 ± 1,64 ммоль/л (p = 0,04) и ЛПНП – с 4,68 ± 1,65 до 3,78 ± 1,28 ммоль/л (p = 0,038). Изменения в данных показателях, а также в уровне ТГ в группе № 2 выявлены не были.</p></sec><sec><title>Заключение</title><p>Заключение. Использование представленной в исследовании фитокомпозиции позволило статистически значимо снизить уровень ЛПНП в  крови у постковидных пациентов – более чем на 0,9 ± 1,85 ммоль/л. Применение фитопрепаратов с  целью снижения риска развития кардиоваскулярных событий у пациентов, перенёсших НКИ, является перспективным направлением, требующим более детальных углублённых исследований.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Cardiovascular events are the main threat in the post-COVID period, and  their risk is  increased in  patients who have had a  new coronavirus infection (SARS-CoV-2). In this regard, the  direction of  studying the  correction of  already well-studied modifiable risk factors is of particular relevance. One of such factors is certainly dyslipidemia.</p></sec><sec><title>The aim</title><p>The aim. To study the level of blood lipids in patients after new coronavirus infection and the possibility of its correction during rehabilitation in sanatorium conditions with the additional use of the phytotherapy.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The study included 50 people who, according to their medical history, had suffered from SARS-CoV-2 infection and were admitted to sanatorium treatment. All patients underwent a course of rehabilitation measures lasting 20 days. Before and after the course of rehabilitation, patients underwent laboratory analysis, which included the main biochemical parameters, including total cholesterol, lowdensity lipoproteins, high-density lipoproteins and triglycerides. The respondents were divided into two groups – experimental (group 1; n = 21) and control (group 2; n = 29). Patients from group 1 received tea from a phytocomposition in addition to standard measures.</p></sec><sec><title>Results</title><p>Results. In  the  group receiving tea based on  herbal phytocomposition, there was a statistically significant decrease in total cholesterol from 6.91 ± 1.75 to  5.9  ±  1.64  mmol/l (p  =  0.04) and  low-density lipoproteins from 4.68  ±  1.65 to  3.78  ±  1.28  mmol/l (p  =  0.038). No  changes were detected in  these indicators, as well as in the level of triglycerides in group 2.</p></sec><sec><title>Conclusion</title><p>Conclusion. The  use of  the  phytocomposition presented in  the  study during the course allowed a statistically significant reduction in low-density lipoproteins levels in the blood of post-Covid patients by more than 0.9 ± 1.85 mmol/l. The use of phytopreparations in order to reduce the risk of cardiovascular events in patients who have undergone new coronavirus infection is a promising area that requires more detailed in-depth studies.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>SARS-CoV-2</kwd><kwd>холестерин</kwd><kwd>ЛПНП</kwd><kwd>постковид</kwd><kwd>фитотерапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>SARS-CoV-2</kwd><kwd>cholesterol</kwd><kwd>low-density lipoproteins</kwd><kwd>post-Covid</kwd><kwd>phytotherapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">COVID-19 coronavirus pandemic worldometer. URL: https://www.worldometers.info/coronavirus [date of access: 18.04.2024].</mixed-citation><mixed-citation xml:lang="en">COVID-19 coronavirus pandemic worldometer. URL:  https://www.worldometers.info/coronavirus [date of  access: 18.04.2024].</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chuang HJ, Lin CW, Hsiao MY, Wang TG, Liang HW. Long COVID and rehabilitation. J Formos Med Assoc. 2024; 123(1): S61- S69. doi: 10.1016/j.jfma.2023.03.022</mixed-citation><mixed-citation xml:lang="en">Chuang HJ, Lin CW, Hsiao MY, Wang TG, Liang HW. Long COVID and rehabilitation. J Formos Med Assoc. 2024; 123(1): S61- S69. doi: 10.1016/j.jfma.2023.03.022</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Mitrani RD, Dabas N, Alfadhli J, Lowery MH, Best TM, Hare JM, et al. Long-term cardiac surveillance and outcomes of COVID-19 patients. Trends Cardiovasc Med. 2022; 32(8): 465-475. doi: 10.1016/j.tcm.2022.06.003</mixed-citation><mixed-citation xml:lang="en">Mitrani  RD, Dabas  N, Alfadhli  J, Lowery  MH, Best TM, Hare  JM, et  al. Long-term cardiac surveillance and  outcomes of COVID-19 patients. Trends Cardiovasc Med. 2022; 32(8): 465-475. doi: 10.1016/j.tcm.2022.06.003</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vosko I, Zirlik A, Bugger H. Impact of COVID-19 on cardiovascular disease. Viruses. 2023; 15(2): 508. doi: 10.3390/v15020508</mixed-citation><mixed-citation xml:lang="en">Vosko I, Zirlik A, Bugger H. Impact of COVID-19 on cardiovascular disease. Viruses. 2023; 15(2): 508. doi:  10.3390/v15020508</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Chilosi M, Doglioni C, Ravaglia C, Piciucchi S, Dubini A, Stefanizzi L, et al. COVID-19. Biology, pathophysiology, and immunology: A pathologist view. Pathologica. 2023; 115(5): 248-256. doi: 10.32074/1591-951X-954</mixed-citation><mixed-citation xml:lang="en">Chilosi  M, Doglioni  C, Ravaglia  C, Piciucchi  S, Dubini  A, Stefanizzi  L, et  al. COVID-19. Biology, pathophysiology, and  immunology: A pathologist view. Pathologica. 2023; 115(5): 248-256. doi: 10.32074/1591-951X-954</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022; 43(4): 611-653. doi: 10.1210/endrev/bnab037</mixed-citation><mixed-citation xml:lang="en">Berberich AJ, Hegele RA. A modern approach to dyslipidemia. Endocr Rev. 2022; 43(4): 611-653. doi: 10.1210/endrev/bnab037</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111-188. doi: 10.1093/eurheartj/ehz455</mixed-citation><mixed-citation xml:lang="en">Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur Heart  J. 2020; 41(1): 111-188. doi: 10.1093/eurheartj/ehz455</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Huang W, Xiao J, Ji J, Chen L. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Elife. 2021; 10: e73873. doi: 10.7554/eLife.73873</mixed-citation><mixed-citation xml:lang="en">Huang W, Xiao J, Ji J, Chen L. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. Elife. 2021; 10: e73873. doi: 10.7554/eLife.73873</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Grewal T, Nguyen MKL, Buechler C. Cholesterol and COVID19-therapeutic opportunities at the host/virus interface during cell entry. Life Sci Alliance. 2024; 7(5): e202302453. doi: 10.26508/lsa.202302453</mixed-citation><mixed-citation xml:lang="en">Grewal T, Nguyen MKL, Buechler C. Cholesterol and COVID19-therapeutic opportunities at  the  host/virus interface during cell entry. Life Sci Alliance. 2024; 7(5): e202302453. doi: 10.26508/lsa.202302453</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022; 612(7941): 758-763. doi: 10.1038/s41586-022-05542-y</mixed-citation><mixed-citation xml:lang="en">Stein  SR, Ramelli  SC, Grazioli  A, Chung  JY, Singh  M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022; 612(7941): 758-763. doi: 10.1038/s41586-022-05542-y</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart J. 2022; 43(34): 3198-3208. doi: 10.1093/eurheartj/ehab841</mixed-citation><mixed-citation xml:lang="en">Tokgözoğlu L, Libby P. The dawn of a new era of targeted lipid-lowering therapies. Eur Heart  J. 2022; 43(34): 3198-3208. doi: 10.1093/eurheartj/ehab841</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Attardo S, Musumeci O, Velardo D, Toscano A. Statins neuromuscular adverse effects. Int J Mol Sci. 2022; 23(15): 8364. doi: 10.3390/ijms23158364</mixed-citation><mixed-citation xml:lang="en">Attardo  S, Musumeci  O, Velardo  D, Toscano  A. Statins neuromuscular adverse effects. Int J Mol Sci. 2022; 23(15): 8364. doi: 10.3390/ijms23158364</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ji X, Shi S, Liu B, Shan M, Tang D, Zhang W, et al. Bioactive compounds from herbal medicines to manage dyslipidemia. Biomed Pharmacother. 2019; 118: 109338. doi: 10.1016/j.biopha.2019.109338</mixed-citation><mixed-citation xml:lang="en">Ji X, Shi S, Liu B, Shan M, Tang D, Zhang W, et al. Bioactive compounds from herbal medicines to manage dyslipidemia. Biomed Pharmacother. 2019; 118: 109338. doi:  10.1016/j.biopha.2019.109338</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Olennikov DN, Kashchenko NI. Marigold metabolites: Diversity and separation methods of calendula genus phytochemicals from 1891 to 2022. Molecules. 2022; 27(23): 8626. doi: 10.3390/molecules27238626</mixed-citation><mixed-citation xml:lang="en">Olennikov  DN, Kashchenko  NI. Marigold metabolites: Diversity and separation methods of calendula genus phytochemicals from 1891 to 2022. Molecules. 2022; 27(23): 8626. doi: 10.3390/molecules27238626</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bonaterra GA, Bronischewski K, Hunold P, Schwarzbach H, Heinrich EU, Fink C, et al. Anti-inflammatory and anti-oxidative effects of Phytohustil® and root extract of Althaea officinalis L. on macrophages in vitro. Front Pharmacol. 2020; 11: 290. doi: 10.3389/fphar.2020.00290</mixed-citation><mixed-citation xml:lang="en">Bonaterra GA, Bronischewski K, Hunold P, Schwarzbach H, Heinrich  EU, Fink  C, et  al. Anti-inflammatory and  anti-oxidative effects of  Phytohustil® and  root extract of Althaea officinalis  L. on  macrophages in vitro. Front Pharmacol. 2020; 11: 290. doi: 10.3389/fphar.2020.00290</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Zhakipbekov K, Turgumbayeva A, Issayeva R, Kipchakbayeva A, Kadyrbayeva G, Tleubayeva M, et al. Antimicrobial and other biomedical properties of extracts from Plantago major, Plantaginaceae. Pharmaceuticals (Basel). 2023; 16(8): 1092. doi: 10.3390/ph16081092</mixed-citation><mixed-citation xml:lang="en">Zhakipbekov  K, Turgumbayeva  A, Issayeva  R, Kipchakbayeva  A, Kadyrbayeva  G, Tleubayeva  M, et  al. Antimicrobial and  other biomedical properties of  extracts from Plantago major, Plantaginaceae. Pharmaceuticals (Basel). 2023; 16(8): 1092. doi: 10.3390/ph16081092</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Burlou-Nagy C, Bănică F, Jurca T, Vicaș LG, Marian E, Muresan ME, et al. Echinacea purpurea (L.) Moench: Biological and pharmacological properties. A Review. Plants (Basel). 2022; 11(9): 1244. doi: 10.3390/plants11091244</mixed-citation><mixed-citation xml:lang="en">Burlou-Nagy  C, Bănică  F, Jurca T, Vicaș  LG, Marian  E, Muresan  ME, et  al. Echinacea purpurea (L.) Moench: Biological and  pharmacological properties. A Review. Plants (Basel). 2022; 11(9): 1244. doi: 10.3390/plants11091244</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sah A, Naseef PP, Kuruniyan MS, Jain GK, Zakir F, Aggarwal G. A comprehensive study of therapeutic applications of chamomile. Pharmaceuticals (Basel). 2022; 15(10): 1284. doi: 10.3390/ph15101284</mixed-citation><mixed-citation xml:lang="en">Sah  A, Naseef  PP, Kuruniyan  MS, Jain  GK, Zakir  F, Aggarwal  G. A  comprehensive study of  therapeutic applications of  chamomile. Pharmaceuticals (Basel). 2022; 15(10): 1284. doi: 10.3390/ph15101284</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Буданцев А.Л., Приходько В.А., Варганова И.В., Оковитый С.В. Биологическая активность Hypericum perforatum L. (Hypericaceae): обзор. Фармация и фармакология. 2021; 9(1): 17-31. 10.19163/2307-9266-2021-9-1-17-31</mixed-citation><mixed-citation xml:lang="en">Budantsev AL, Prikhodko VA, Varganova IV, Okovitiy SV. Biological activity of Hypericum perforatum L. (Hypericaceae): A review. Pharmacy &amp; Pharmacology. 2021; 9(1): 17-31. (In Russ.). doi: 10.19163/2307-9266-2021-9-1-17-31</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sharifi-Rad J, Quispe C, Herrera-Bravo J, Belén LH, Kaur R, Kregiel D, et al. Glycyrrhiza genus: Enlightening phytochemical components for pharmacological and health-promoting abilities. Oxid Med Cell Longev. 2021; 2021: 7571132. doi: 10.1155/2021/7571132</mixed-citation><mixed-citation xml:lang="en">Sharifi-Rad J, Quispe C, Herrera-Bravo J, Belén LH, Kaur R, Kregiel D, et al. Glycyrrhiza genus: Enlightening phytochemical components for pharmacological and health-promoting abilities. Oxid Med Cell Longev. 2021; 2021: 7571132. doi: 10.1155/2021/7571132</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Das B, Rabalais J, Kozan P, Lu T, Durali N, Okamoto K, et al. The effect of a fennel seed extract on the STAT signaling and intestinal barrier function. PLoS One. 2022; 17(7): e0271045. doi: 10.1371/journal.pone.0271045</mixed-citation><mixed-citation xml:lang="en">Das B, Rabalais J, Kozan P, Lu T, Durali N, Okamoto K, et al. The effect of a fennel seed extract on the STAT signaling and intestinal barrier function. PLoS One. 2022; 17(7): e0271045. doi: 10.1371/journal.pone.0271045</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Adel Mehraban MS, Tabatabaei-Malazy O, Rahimi R, Daniali M, Khashayar P, Larijani B. Targeting dyslipidemia by herbal medicines: A systematic review of meta-analyses. J Ethnopharmacol. 2021; 280: 114407. doi: 10.1016/j.jep.2021.114407</mixed-citation><mixed-citation xml:lang="en">Adel Mehraban MS, Tabatabaei-Malazy O, Rahimi R, Daniali M, Khashayar P, Larijani B. Targeting dyslipidemia by herbal medicines: A systematic review of meta-analyses. J Ethnopharmacol. 2021; 280: 114407. doi: 10.1016/j.jep.2021.114407</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Gyawali D, Vohra R, Orme-Johnson D, Ramaratnam S, Schneider RH. A systematic review and meta-analysis of ayurvedic herbal preparations for hypercholesterolemia. Medicina (Kaunas). 2021; 57(6): 546. doi: 10.3390/medicina57060546</mixed-citation><mixed-citation xml:lang="en">Gyawali  D, Vohra  R, Orme-Johnson  D, Ramaratnam  S, Schneider RH. A systematic review and meta-analysis of ayurvedic herbal preparations for hypercholesterolemia. Medicina (Kaunas). 2021; 57(6): 546. doi: 10.3390/medicina57060546</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ba Tuyen P, Huyen TT, Hang DTT, Thi Van Anh P. A novel herbal medicine for dyslipidemia: Assessments in experimental models. Evid Based Complement Alternat Med. 2021; 2021: 5529744. doi: 10.1155/2021/5529744</mixed-citation><mixed-citation xml:lang="en">Ba Tuyen P, Huyen TT, Hang DTT, Thi Van Anh P. A novel herbal medicine for  dyslipidemia: Assessments in  experimental models. Evid Based Complement Alternat Med. 2021; 2021: 5529744. doi: 10.1155/2021/5529744</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Qin Y, Xia M, Ma J, Hao Y, Liu J, Mou H, et al. Anthocyanin supplementation improves serum LDL- and HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. Am J Clin Nutr. 2009; 90(3): 485-492. doi: 10.3945/ajcn.2009.27814</mixed-citation><mixed-citation xml:lang="en">Qin Y, Xia M, Ma J, Hao Y, Liu J, Mou H, et al. Anthocyanin supplementation improves serum LDL- and  HDL-cholesterol concentrations associated with the inhibition of cholesteryl ester transfer protein in dyslipidemic subjects. Am J Clin Nutr. 2009; 90(3): 485-492. doi: 10.3945/ajcn.2009.27814</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Ren K, Jiang T, Zhao GJ. Quercetin induces the selective uptake of HDL-cholesterol via promoting SR-BI expression and the activation of the PPARγ / LXRα pathway. Food Funct. 2018; 9(1): 624-635. doi: 10.1039/c7fo01107e</mixed-citation><mixed-citation xml:lang="en">Ren  K, Jiang T, Zhao  GJ. Quercetin induces the  selective uptake of  HDL-cholesterol via  promoting SR-BI expression and the activation of the PPARγ / LXRα pathway. Food Funct. 2018; 9(1): 624-635. doi: 10.1039/c7fo01107e</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sun L, Li E, Wang F, Wang T, Qin Z, Niu S, et al. Quercetin increases macrophage cholesterol efflux to inhibit foam cell formation through activating PPARγ-ABCA1 pathway. Int J Clin Exp Pathol. 2015; 8(9): 10854-10860.</mixed-citation><mixed-citation xml:lang="en">Sun L, Li E, Wang F, Wang T, Qin Z, Niu S, et al. Quercetin increases macrophage cholesterol efflux to inhibit foam cell formation through activating PPARγ-ABCA1 pathway. Int J Clin Exp Pathol. 2015; 8(9): 10854-10860.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Zou J, Feng D. Lycopene reduces cholesterol absorption through the downregulation of Niemann-Pick C1-like 1 in Caco-2 cells. Mol Nutr Food Res. 2015; 59(11): 2225-2230. doi: 10.1002/mnfr.201500221</mixed-citation><mixed-citation xml:lang="en">Zou J, Feng D. Lycopene reduces cholesterol absorption through the downregulation of Niemann-Pick C1-like 1 in Caco-2 cells. Mol Nutr Food Res. 2015; 59(11): 2225-2230. doi:  10.1002/mnfr.201500221</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Francisco V, Figueirinha A, Costa G, Liberal J, Ferreira I, Lopes MC, et al. The flavone luteolin inhibits liver X receptor activation. J Nat Prod. 2016; 79(5): 1423-1428. doi: 10.1021/acs.jnatprod.6b00146</mixed-citation><mixed-citation xml:lang="en">Francisco V, Figueirinha A, Costa G, Liberal J, Ferreira I, Lopes MC, et al. The flavone luteolin inhibits liver X receptor activation. J Nat Prod. 2016; 79(5): 1423-1428. doi: 10.1021/acs.jnatprod.6b00146</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Lin Y, Vermeer MA, Trautwein EA. Triterpenic acids present in hawthorn lower plasma cholesterol by inhibiting intestinal ACAT activity in hamsters. Evid Based Complement Alternat Med. 2011; 2011: 801272. doi: 10.1093/ecam/nep007</mixed-citation><mixed-citation xml:lang="en">Lin Y, Vermeer MA, Trautwein EA. Triterpenic acids present in hawthorn lower plasma cholesterol by inhibiting intestinal ACAT activity in hamsters. Evid Based Complement Alternat Med. 2011; 2011: 801272. doi: 10.1093/ecam/nep007</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
